Physician profile
John Hunter Leigh
NPI 1295706000
$2,139.31
in general payments reported to CMS, 2019-2025
19 companies · $321 in 2025
The $321 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $999 · 2020: $239 · 2021: $151 · 2022: $157 · 2023: $20.28 · 2024: $252 · 2025: $321.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $594.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $593.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $557.03 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Astrazeneca Pharmaceuticals LP | $273.39 | 2019-2025 | Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $214.80 | 2019-2022 | |
| Amgen INC. | $202.29 | 2019-2025 | Otezla, Repatha |
| Pfizer INC. | $159.74 | 2019-2020 | |
| Lilly USA, LLC | $150.50 | 2019-2024 | Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $145.95 | 2019-2022 | |
| Dexcom, INC. | $78.96 | 2022-2025 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $70.99 | 2019 | |
| Abbvie INC. | $61.88 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $55.21 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $50.87 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $30.15 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $24.75 | 2019 | |
| Exact Sciences Corporation | $16.20 | 2024 | Cologuard Collection Kit |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $12.63 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $11.93 | 2019 | |
| Astellas Pharma US INC | $11.12 | 2019 | |
| Allergan, INC. | $10.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Leigh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.